Loading clinical trials...

Rare Tumours in Children and Adolescents (STEP) | Clinical Trials | Clareo Health

RECRUITING

Rare Tumours in Children and Adolescents (STEP)

Rare Tumours in Children and Adolescents (STEP 2.0) - Register for the Documentation of Rare Tumours in Children and Adolescents

NCT05773651•University Hospital Tuebingen

View on ClinicalTrials.gov

Summary

The aim of the STEP registry is to collect and evaluate experience and data on the diagnosis and treatment of rare childhood tumors in order to use the knowledge gained to improve the treatment prospects for our patients. The rarity of a disease should not be a disadvantage for the young patients.

Detailed Description

The objective of the STEP registry is to optimise the diagnosis and treatment of patients with rare tumour diseases in childhood and adolescence. Therefore, a continuous prospective collection of clinical data on rare paediatric tumours is conducted to improve the understanding of these tumours. Beyond analysis of clinical data, further scientific research on the biological and molecular genetic characteristics of these tumours is performed. These data and a close collaboration with international partners, especially the European EXPeRT group, enable the improvement of treatment recommendations for these tumours along with establishment a global interdisciplinary network of rare tumour specialists.

Eligibility

Age

0 - 18 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of a rare solid tumor
•Age at diagnosis: Neonatal period to 18 years (In the case of young adults, registration in the database and/or referral to advisory contact persons within the framework of the competence network can take place upon request and after declaration of consent.)
•Information, education, written consent of the patient or the guardian
•Not recorded in any of the existing clinical studies/ registers of the German Society for Pediatric Oncology and Hematology (GPOH)

Exclusion Criteria

•Registration of the tumor diagnosis in a prospective therapy study/ another clinical registry of the GPOH
•Lack of information, explanation and/or written consent of the patient or the legal guardian.

Locations (1)

University Hospital Tübingen

Tübingen, Germany

Key Dates

Start Date

January 11, 2023

Primary Completion Date

January 1, 2050

Completion Date

January 1, 2055

Last Updated

October 1, 2024

Enrollment

10,000

ESTIMATED participants

Conditions

Rare Diseases

Interventions

Data collection

OTHER

Contacts

Ines Brecht, PD Dr. med.

CONTACT

+49 7071 29 ines.brecht@med.uni-tuebingen.de

Michael Abele, Dr. med.

CONTACT

+49 7071 29 michael.abele@med.uni-tuebingen.de

Genetic Analysis of Uncommon Disease Presentations in Non-US Populations

NCT06595940

Undiagnosed DiseasesRare Diseases

View study

RECRUITING

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

NCT07247279

Rare DiseasesGeneralized Myasthenia Gravis (gMG)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 1, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Rare Tumours in Children and Adolescents (STEP)

Inclusion Criteria

Exclusion Criteria

Genetic Analysis of Uncommon Disease Presentations in Non-US Populations

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Genetic Study to Determine the Cause of Birth Defects in Newborns in Texas

Institutional Registry of Rare Diseases

DeciFace: Decipher the Influence of Ethnic Backgrounds on the Facial Dysmorphic Features of Rare Mendelian Disorders

Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN